

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT3924193

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
AKIN AKINC	10/01/2015
MARTIN MAIER	10/01/2015
VARUN KUMAR	06/11/2016
RECEIVING PARTY DATA	
Name:	ALNYLAM PHARMACEUTICALS, INC.
Street Address:	300 THIRD STREET
City:	CAMBRIDGE
State/Country:	MASSACHUSETTS
Postal Code:	02142
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	14650264
CORRESPONDENCE DATA	
Fax Number:	(917)332-3773
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	212-885-5000
Email:	jyeddo@blankrome.com
Correspondent Name:	BLANK ROME LLP
Address Line 1:	THE CHRYSLER BUILDING
Address Line 2:	405 LEXINGTON AVE.
Address Line 4:	NEW YORK, NEW YORK 10174
ATTORNEY DOCKET NUMBER:	135399.03902
NAME OF SUBMITTER:	JUDY YEDDO
SIGNATURE:	/Judy Yeddo/
DATE SIGNED:	06/17/2016
Total Attachments: 6	
source=Recordation#page1.tif	
source=Declaration#page1.tif	
source=Declaration#page2.tif	

source=Declaration#page3.tif

source=Declaration#page4.tif

source=Declaration#page5.tif

RECORDATION FORM COVER SHEET PATENTS ONLY

To the Director of the U.S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

1. Name of conveying party(ies) Akin AKINC (10/01/2015), Martin MAIER (10/01/2015), and Varun KUMAR (06/11/2016) Additional name(s) of conveying party(ies) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	2. Name and address of receiving party(ies) Name: <u>ALNYLAM PHARMACEUTICALS, INC.</u> Internal Address: _____ Street Address: _____ 300 Third Street City: <u>Cambridge</u> State: <u>Massachusetts</u> Country: <u>United States of America</u> Zip: <u>02142</u> Additional name(s) & address(es) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
3. Nature of conveyance/Execution Date(s): Execution Date(s) <u>in parentheses after inventor name</u> <input checked="" type="checkbox"/> Assignment <input type="checkbox"/> Merger <input type="checkbox"/> Change of Name <input type="checkbox"/> Security Agreement <input type="checkbox"/> Joint Research Agreement <input type="checkbox"/> Government Interest Assignment <input type="checkbox"/> Executive Order 9424, Confirmatory License <input type="checkbox"/> Other _____	4. Application or patent number(s): <input type="checkbox"/> This document serves as an Oath/Declaration (37 CFR 1.63). A. Patent Application No.(s) <u>14/650,264</u> B. Patent No.(s) Additional numbers attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
5. Name and address to whom correspondence concerning document should be mailed: Jay P. Lessler Name: <u>BLANK ROME LLP</u> Internal Address: _____ Street Address: <u>The Chrysler Building</u> <u>405 Lexington Ave.</u> City: <u>New York</u> State: <u>NY</u> Zip: <u>10174-0208</u> Phone Number: <u>(212) 885-5000</u> Docket Number: <u>135399.03902</u> Email Address: <u>patents@blankrome.com</u>	6. Total number of applications and patents involved: <u>1</u> 7. Total fee (37 CFR 1.21(h) & 3.41) \$ <u>0.00</u> <input checked="" type="checkbox"/> Authorized to be charged to deposit account <input type="checkbox"/> Enclosed <input type="checkbox"/> None required (government interest not affecting title)
9. Signature: <u>/Jay P. Lessler/</u> Signature <u>Jay P. Lessler - 41,151</u> Name of Person Signing	8. Payment Information Deposit Account Number <u>02-2555</u> Authorized User Name <u>Jay P. Lessler</u> Total number of pages including cover sheet, attachments, and documents: 6

Documents to be recorded (including cover sheet) should be faxed to (571) 273-0140, or mailed to:
Mail Stop Assignment Recordation Services, Director of the USPTO, P.O.Box 1450, Alexandria, V.A. 22313-1450

**COMBINED ASSIGNMENT & DECLARATION
FOR UTILITY OR DESIGN PATENT APPLICATIONS**

ASSIGNMENT

THIS ASSIGNMENT made by Akin AKINC, Martin MAIER, and Varun KUMAR (hereinafter referred to as Assignors), each residing at 300 Third Street, Cambridge, Massachusetts 02142;

WHEREAS, Assignors have invented certain new and useful improvements in IMPROVED NUCLEIC ACID LIPID PARTICLE FORMULATIONS, set forth in U.S. Patent Application No. 14/650,264, filed June 5, 2015, International Patent Application No. PCT/US13/73181, filed December 4, 2013, and U.S. Patent Application No. 61/734,736, filed December 7, 2012; and

WHEREAS, ALNYLAM PHARMACEUTICALS, INC., a Company organized under and pursuant to the laws of Delaware having its principal place of business at 300 Third Street, Cambridge, Massachusetts 02142 (hereinafter referred to as Assignee), is desirous of acquiring the entire right, title and interest in and to said inventions and said applications for Letters Patent of the United States and all other countries in the world, and in and to any Letters Patent of the United States and all other countries in the world to be obtained therefore and thereon.

NOW, THEREFORE, in consideration of One Dollar (\$1.00) and other good and sufficient consideration, the receipt of which is hereby acknowledged, Assignors have sold, assigned, transferred and set over, and by these presents do sell, assign, transfer and set over, unto Assignee, its successors, legal representatives and assigns, the entire right, title and interest in and to the above-mentioned inventions and applications for Letters Patent, and in and to any and all direct and indirect divisions, continuations and continuations-in-part of said applications, and any and all Letters Patent in the United States and all other countries in the world which may be granted therefore and thereon, and reissues, reexaminations and extensions of said Letters Patent, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by Assignee, for its own use and benefit and the use and benefit of its successors, legal representatives and assigns, to the full end of the term or terms for which Letters Patent may be granted and/or extended, as fully and entirely as

the same would have been held and enjoyed by Assignors, had this sale and assignment not been made.

AND for the same consideration, Assignors hereby represent and warrant to Assignee, its successors, legal representatives and assigns, that, at the time of execution and delivery of these presents, except for any rights, titles and/or interests that have arisen to Assignee under law or that have already been transferred to Assignee, Assignors are the sole and lawful owners of the entire right, title and interest in and to the said inventions and applications for Letters Patent above-mentioned, and that the same are unencumbered and that Assignors have good and full right and lawful authority to sell and convey the same in the manner herein set forth.

AND for the same consideration, Assignors hereby covenant and agree to and with Assignee, its successors, legal representatives and assigns, that Assignors will sign all papers and documents, take all lawful oaths and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of any Letters Patent and applications for Letters Patent for said inventions, without charge to Assignee, its successors, legal representatives and assigns, whenever counsel of Assignee, or counsel of its successors, legal representatives and assigns, shall advise: that any proceeding in connection with said inventions, or said Patent application for Letters Patent, or any proceeding in connection with any Letters Patent or applications for Letters Patent for said inventions in any country, including but not limited to interference proceedings, is lawful and desirable; or, that any division, continuation or continuation-in-part of any application for Letters Patent, or any reissue, reexamination or extension of any Letters Patent, to be obtained thereon, is lawful and desirable.

AND Assignors hereby request the Commissioner for Patents and Trademarks to issue said Letters Patent of the United States to Assignee, as Assignee of said inventions and the Letters Patent to be issued thereon, for the sole use and benefit of Assignee, its successors, legal representatives and assigns.

AND Assignors acknowledge an obligation of assignment of this invention to Assignee at the time the invention was made.

DECLARATION

As a below named inventor, I hereby declare that:

This declaration is directed to the patent application entitled:

IMPROVED NUCLEIC ACID LIPID PARTICLE FORMULATIONS

the specification of which was filed on June 5, 2015 as U.S. Patent Application No. 14/650,264.


The above-identified application was made or authorized to be made by me.


I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I have reviewed and understand the contents of the above-identified application.

I am aware of the duty to disclose to the Office all information known to me to be material to patentability as defined in 37 C.F.R. 1.56.

I hereby acknowledge that any willful false statement made in this Declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

Date: October 1, 2015 Signature: 
Akın Akinc

Date: Oct. 1, 2015 Signature: 
Martin Maier

Date: _____ Signature: _____
Varun Kumar

I hereby acknowledge that any willful false statement made in this Declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.


Date: _____

Signature: _____
Akin Akinc

Date: _____

Signature: _____
Martin Maier

Date: 06/11/16

Signature: 
Varun Kumar